Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?
Journal Title: International Journal of Immunotherapy and Cancer Research - Year 2015, Vol 1, Issue 1
Abstract
Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons. Case presentation: We present a female patient to which the disease has been monitored for 14 years, during which she has been treated with alpha-interferon, cladribine and rituximab. The monitorization and conduct of such patients are discussed, and an analysis of the therapeutic possibilities at this stage is performed, which can be useful for physicians and researchers. Conclusion: An individual assessment of patient at diagnosis and during evolution is needed to determine which drug or drug combination is indicated and how many therapeutic lines are needed.
Authors and Affiliations
Mihaila Romeo-Gabriel
Keywords
Related Articles
- EP ID EP348689
- DOI 10.17352/2455-8591.000002
- Views 103
- Downloads 0
A Study of Glucosylceramide Synthase and Glycolytic Pathway Enzymes in Patients with Hypereosinophilia
Glucosylceramide synthase is the rate limiting enzyme in ceramide glycosylation and shifts the balance between ceramide and glycosphingolipids towards proliferation and survival of cancer cells. Increased glucose availab...
Regulation of Protein Degradation and Homeostasis by the Cytokine- Inducible Deubiquitinating Enzymes
Ubiquitin-proteasome system (UPS) is the major signaling pathway responsible for regulating protein turnover in cells. Deubiquitinating enzymes (DUBs) have an important role in this signaling pathway by eliminating ubiqu...
SMART Drug Based Targeted Delivery: A New Paradigm for Nanomedicine Strategies
Introduction: Targeted drug delivery systems are nanoscale drug carrier molecules designed for improving the communication of cellular and molecular components and biodistribution of tumour targeted drug (chemo) therapeu...
Adiponectin Regulates the Development and Progression of MCA-Induced Sarcoma in Mice
Background: Sarcomas are malignant tumors with low survival rates and remain refractory to the current therapeutic methods. Adiponectin plays crucial roles in many physiological responses. Studies have shown that adipone...
Anti-VEGF Therapy Induces Proteinuria through Endothelial Disorganization Leading to Nephrin Decrease in Podocytes
Background: VEGF is involved in cancer development by stimulating neo-angiogenesis and tumor proliferation. Anti-angiogenic therapies, especially tyrosine kinase inhibitors such as sunitinib, have significantly improved...